Matching articles for "fluticasone furoate"
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • November 25, 2024; (Issue 1716)
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed here.
Comparison Chart: Some Inhaled Drugs for Treatment of Asthma (online only)
The Medical Letter on Drugs and Therapeutics • November 25, 2024; (Issue 1716)
...
View the Comparison Chart: Some Inhaled Drugs for Treatment of Asthma
Drugs for Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • April 19, 2021; (Issue 1622)
The choice of drugs for treatment of allergic rhinitis
depends on the severity of symptoms and whether
they are intermittent or persistent (see Table...
The choice of drugs for treatment of allergic rhinitis
depends on the severity of symptoms and whether
they are intermittent or persistent (see Table 1).
Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • April 19, 2021; (Issue 1622)
...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • April 19, 2021; (Issue 1622)
...
View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • December 14, 2020; (Issue 1613)
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations
of asthma in the emergency department is not
discussed...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations
of asthma in the emergency department is not
discussed here.
Table: Some Inhaled Drugs for Treatment of Asthma (online only)
The Medical Letter on Drugs and Therapeutics • December 14, 2020; (Issue 1613)
...
View the table: Some Inhaled Drugs for Treatment of Asthma
Table: Correct Use of Inhalers for Asthma (online only)
The Medical Letter on Drugs and Therapeutics • December 14, 2020; (Issue 1613)
...
View the table: Correct Use of Inhalers for Asthma
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Several...
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Several guidelines
and review articles on COPD treatment have been
published in recent years. Treatment of acute
exacerbations is not discussed here.
Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
...
View the Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD
Comparison Table: Inhaled Corticosteroids for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
...
View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD
Table: Correct Use of Inhalers for COPD (online only)
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
...
View the Table: Correct Use of Inhalers for COPD
OTC Drugs for Seasonal Allergies
The Medical Letter on Drugs and Therapeutics • April 22, 2019; (Issue 1570)
Patients with seasonal allergies often experience
nasal itching and congestion, sneezing, rhinorrhea,
and itchy, watery eyes. Oral, intranasal, and ophthalmic
preparations are widely available over the...
Patients with seasonal allergies often experience
nasal itching and congestion, sneezing, rhinorrhea,
and itchy, watery eyes. Oral, intranasal, and ophthalmic
preparations are widely available over the counter
(OTC) for relief of symptoms. Prescription products for
management of allergic rhinitis and allergic conjunctivitis
are reviewed separately.
Trelegy Ellipta - A Three-Drug Inhaler for COPD
The Medical Letter on Drugs and Therapeutics • May 21, 2018; (Issue 1547)
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose
combination of the inhaled corticosteroid (ICS)
fluticasone furoate, the long-acting antimuscarinic
agent (LAMA) umeclidinium, and the...
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose
combination of the inhaled corticosteroid (ICS)
fluticasone furoate, the long-acting antimuscarinic
agent (LAMA) umeclidinium, and the long-acting
beta2-agonist (LABA) vilanterol. It is available as a dry
powder inhaler for once-daily maintenance treatment
of COPD and to reduce COPD exacerbations in patients
with a history of exacerbations. Trelegy Ellipta is
the first three-drug inhaler for treatment of COPD to
become available in the US.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • August 28, 2017; (Issue 1528)
The goal of asthma treatment is to control symptoms
and prevent exacerbations. Management of acute
exacerbations of asthma is not discussed...
The goal of asthma treatment is to control symptoms
and prevent exacerbations. Management of acute
exacerbations of asthma is not discussed here.
Comparison Table: Some Inhaled Drugs for Treatment of Asthma (online only)
The Medical Letter on Drugs and Therapeutics • August 28, 2017; (Issue 1528)
...
View the Comparison Table: Some Inhaled Drugs for Treatment of Asthma
Comparison Table: Correct Use of Inhalers for Asthma (online only)
The Medical Letter on Drugs and Therapeutics • August 28, 2017; (Issue 1528)
...
View the Comparison Table: Correct Use of Inhalers
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • May 8, 2017; (Issue 1520)
Allergic rhinitis can be classified as seasonal,
perennial, or episodic. It is often associated with
allergic conjunctivitis, rhinosinusitis, and asthma. H1-ANTIHISTAMINES — Oral – Oral...
Allergic rhinitis can be classified as seasonal,
perennial, or episodic. It is often associated with
allergic conjunctivitis, rhinosinusitis, and asthma.
H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • May 8, 2017; (Issue 1520)
...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
OTC Fluticasone Furoate Nasal Spray (Flonase Sensimist) for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • April 24, 2017; (Issue 1519)
The nasal spray formulation of the corticosteroid
fluticasone furoate is now available over the
counter (OTC) as Flonase Sensimist Allergy Relief
(GSK) in the same strength as the prescription
product...
The nasal spray formulation of the corticosteroid
fluticasone furoate is now available over the
counter (OTC) as Flonase Sensimist Allergy Relief
(GSK) in the same strength as the prescription
product (Veramyst) for treatment of seasonal or
perennial allergic rhinitis. It is the fourth intranasal
corticosteroid to become available OTC.
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Updated...
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Updated guidelines
for treatment of COPD have been published in
recent years.
Comparison Table: Some Inhaled Corticosteroids for COPD (online only)
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
...
View the Comparison Table: Some Inhaled Corticosteroids for COPD
Table: Correct Use of Inhalers for COPD (online only)
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
...
View the Table: Correct Use of Inhalers for COPD
Fluticasone Furoate (Arnuity Ellipta) for Asthma
The Medical Letter on Drugs and Therapeutics • May 25, 2015; (Issue 1469)
The FDA has approved Arnuity Ellipta (GSK), a single-agent
inhaler containing the corticosteroid fluticasone
furoate, for once-daily maintenance treatment of
asthma in patients ≥12 years old. Fluticasone...
The FDA has approved Arnuity Ellipta (GSK), a single-agent
inhaler containing the corticosteroid fluticasone
furoate, for once-daily maintenance treatment of
asthma in patients ≥12 years old. Fluticasone furoate
is also available in combination with the long-acting
beta2-agonist vilanterol as Breo Ellipta for treatment
of asthma and COPD.
A 4-Drug Combination (Viekira Pak) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • February 2, 2015; (Issue 1461)
The FDA has approved Viekira Pak (Abbvie), a fixed-dose
combination of two new direct-acting antiviral
agents (ombitasvir, paritaprevir) with the pharmacologic
enhancer ritonavir in one tablet, co-packaged...
The FDA has approved Viekira Pak (Abbvie), a fixed-dose
combination of two new direct-acting antiviral
agents (ombitasvir, paritaprevir) with the pharmacologic
enhancer ritonavir in one tablet, co-packaged with
a third new direct-acting antiviral agent (dasabuvir) in
a second tablet, for oral treatment of chronic hepatitis
C virus (HCV) genotype 1 infection. Genotype 1 is
responsible for 70-80% of HCV infections in the US.
Olodaterol (Striverdi Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • January 5, 2015; (Issue 1459)
Olodaterol (Striverdi Respimat – Boehringer Ingelheim),
a new inhaled long-acting beta2-agonist, has been
approved by the FDA for once-daily maintenance
treatment of airflow obstruction in patients...
Olodaterol (Striverdi Respimat – Boehringer Ingelheim),
a new inhaled long-acting beta2-agonist, has been
approved by the FDA for once-daily maintenance
treatment of airflow obstruction in patients with
chronic obstructive pulmonary disease (COPD). It is
not approved for treatment of acute exacerbations of
COPD or for treatment of asthma. Olodaterol is the third
long-acting beta2-agonist to be approved by the FDA
for once-daily use; indacaterol (Arcapta Neohaler),
which is available as a single agent, and vilanterol,
which is available only in fixed-dose combinations
with the long-acting anticholinergic umeclidinium
(Anoro Ellipta) or the corticosteroid fluticasone furoate
(Breo Ellipta), were approved earlier.
Anoro Ellipta: An Inhaled Umeclidinium/Vilanterol Combination for COPD
The Medical Letter on Drugs and Therapeutics • April 14, 2014; (Issue 1440)
The FDA has approved an inhaled fixed-dose
combination of the long-acting anticholinergic
umeclidinium (ue mek" li din' ee um) and the long-acting
beta2-adrenergic agonist (LABA) vilanterol
(Anoro Ellipta...
The FDA has approved an inhaled fixed-dose
combination of the long-acting anticholinergic
umeclidinium (ue mek" li din' ee um) and the long-acting
beta2-adrenergic agonist (LABA) vilanterol
(Anoro Ellipta – GSK/Theravance) for once-daily
maintenance treatment of chronic obstructive
pulmonary disease (COPD). Anoro Ellipta is the first
product available in the US that combines two long-acting
bronchodilators in a single delivery device.
An OTC Corticosteroid Nasal Spray for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • November 11, 2013; (Issue 1429)
The FDA has approved the over-the-counter (OTC)
sale of Nasacort Allergy 24HR (Sanofi), a triamcinolone
acetonide nasal spray previously available only
by prescription as Nasacort AQ. The OTC product,
which...
The FDA has approved the over-the-counter (OTC)
sale of Nasacort Allergy 24HR (Sanofi), a triamcinolone
acetonide nasal spray previously available only
by prescription as Nasacort AQ. The OTC product,
which is scheduled to be marketed in the spring of
2014, will be the first corticosteroid nasal spray that
can be purchased without a prescription in the US.
Nasacort Allergy 24HR is approved for use in patients
≥2 years old with nasal allergy symptoms.
Breo Ellipta: An Inhaled Fluticasone/Vilanterol Combination for COPD
The Medical Letter on Drugs and Therapeutics • September 2, 2013; (Issue 1424)
The FDA has approved an inhaled fixed-dose combination
(Breo Ellipta – GSK/Theravance) of the corticosteroid
fluticasone furoate and the long-acting
beta2-adrenergic agonist (LABA) vilanterol...
The FDA has approved an inhaled fixed-dose combination
(Breo Ellipta – GSK/Theravance) of the corticosteroid
fluticasone furoate and the long-acting
beta2-adrenergic agonist (LABA) vilanterol trifenatate
for once-daily treatment of chronic obstructive pulmonary
disease (COPD).
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • May 1, 2013; (Issue 129)
The use of drugs to prevent and control symptoms of
allergic disorders can be optimized when patients
avoid exposure to specific allergens and/or environmental
conditions that trigger or worsen their...
The use of drugs to prevent and control symptoms of
allergic disorders can be optimized when patients
avoid exposure to specific allergens and/or environmental
conditions that trigger or worsen their symptoms.
Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • October 29, 2012; (Issue 1402)
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and...
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H1-antihistamine and a corticosteroid.
Ciclesonide (Omnaris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • May 5, 2008; (Issue 1285)
Ciclesonide (Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial...
Ciclesonide (Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter
Fluticasone Furoate (Veramyst) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • November 5, 2007; (Issue 1273)
Fluticasone furoate nasal spray (Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone...
Fluticasone furoate nasal spray (Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone propionate nasal spray (Flonase, and others), which is now available generically.
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • August 1, 2007; (Issue 60)
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in...
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in industrialized countries. Pharmacologic treatment of these disorders continues to improve in efficacy and safety. In addition to using drugs to prevent and control the symptoms of their allergic diseases, patients should also be instructed to avoid, if possible, specific allergens and/or environmental conditions that trigger or worsen their symptoms.